Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network

INTRODUCTION: The outcomes of COVID-19 in patients with axial spondyloarthritis (ax-SpA) have not been explored in detail. Tumour necrosis factor inhibitors (TNFi) are commonly used for ax-SpA patients, and how they influence outcomes may have implications on COVID-19 management. METHODS: A nationwi...

Descripción completa

Detalles Bibliográficos
Autores principales: Raiker, Rahul, Pakhchanian, Haig, Kavadichanda, Chengappa, Gupta, Latika, Kardeş, Sinan, Ahmed, Sakir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626282/
https://www.ncbi.nlm.nih.gov/pubmed/34837569
http://dx.doi.org/10.1007/s10067-021-05979-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626282/
https://www.ncbi.nlm.nih.gov/pubmed/34837569
http://dx.doi.org/10.1007/s10067-021-05979-y

Ejemplares similares